GENB CMO granted 42,230 stock options

Generate Biomedicines, Inc. Chief Medical Officer Laurie Anne Lee reported an award of stock options covering 42,230 shares on February 26, 2026.

Rhea-AI Filing Summary

Generate Biomedicines, Inc. Chief Medical Officer Laurie Anne Lee reported an award of stock options covering 42,230 shares on February 26, 2026. These options were granted at an exercise price of $0.00 per share and will vest in 48 equal monthly installments following February 19, 2026, as long as she continues in service.

Insider Trade Summary

Grant/Award: 42,230 shares

Grant/Award 1 txn

Insider Lee Laurie Anne

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	42,230	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 42,230 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GENB Chief Medical Officer Laurie Anne Lee report?

Laurie Anne Lee reported receiving a stock option grant for 42,230 shares. The options were awarded as a form of compensation and are structured to vest gradually over time, aligning her incentives with the company’s long-term performance and service duration.

How many Generate Biomedicines (GENB) options were granted to Laurie Anne Lee?

She was granted stock options covering 42,230 shares of Generate Biomedicines common stock. All 42,230 option shares were reported as directly owned following the transaction, reflecting a new equity award rather than an open-market purchase or sale.

What is the exercise price of Laurie Anne Lee’s GENB stock options?

The reported exercise price of the stock options is $0.00 per share. This indicates a compensatory grant where no cash payment is required to obtain the underlying shares, subject to meeting the vesting and continued service conditions attached to the award.

How do Laurie Anne Lee’s GENB stock options vest over time?

The options vest in 48 equal monthly installments following February 19, 2026. Each month, a portion of the 42,230 options becomes exercisable, provided Laurie Anne Lee continues her service with Generate Biomedicines on each applicable vesting date as specified.

What conditions apply to the vesting of GENB options granted to Laurie Anne Lee?

Vesting is conditioned on Laurie Anne Lee’s continued service with Generate Biomedicines. The footnote states the 42,230 options vest in 48 equal monthly installments after February 19, 2026, only if she remains in service on each scheduled vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Laurie Anne

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		42,230		(1)	02/25/2036	Common Stock	42,230	$0	42,230	D

Explanation of Responses:

1. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.